Clinical Trial: Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710534) titled 'Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN' on July 07.

Brief Summary: This is a single-center randomized phase 2 open-label clinical trial.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Relapsed / Refractory AML High Risk Myelodysplastic Syndrome High Risk Myeloproliferative Neoplasms

Intervention: DRUG: Decitabine-cedazuridine plus venetoclax (DEC-C+VEN)

Decitabine-cedazuridine (DEC-C) dosage per protocol taken by mouth once weekly plus Venetoclax (VEN) 400 milligrams (mg), taken by mouth once weekly

DRUG: Azacitidine plus venetoclax (AZA+VEN)

Azacitidine (AZA) 75 mi...